Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT - Articles - Dermatology · Immunology · Rheumatology

Psoriatic Arthritis

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

J Rheumatol

Provan SA, Ljung L, Kristianslund EK, Michelsen B, Uhlig T, Jonmundsson T, Sexton J, Gudbjornsson B, Di Giuseppe D, Hetland ML, Reynisdottir GB, Glintborg B, Relas H, Aaltonen K, Kvien TK, Askling J

doi: 10.3899/jrheum.2024-0252

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Rheumatoid Arthritis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, Berger S, Rockwitz K, Krüger K, Schneider KM, Regierer AC, Strangfeld A

doi: 10.1016/j.ard.2025.05.014

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: A nationwide cross-sectional study among > 12,000 patients

Rheumatology (Oxford)

Vestergaard SB, Esbensen BA, Midtgaard J, Cromhout PF, Aadahl M, Glintborg B, de Thurah A

doi: 10.1093/rheumatology/keae471

Further Publications Immunology

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Lancet

Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE, VIVID Study Group

doi: 10.1016/S0140-6736(24)01762-8

Rheumatoid Arthritis

Comorbidity in incident rheumatoid arthritis-a nationwide case-control study with bidirectional follow-up

Rheumatology (Oxford)

Batko B, Szeląg M, Krajewska-Włodarczyk M, Żuber Z, Orleański M, Podwójcic K, Sowiński J, Świderek M, Maluchnik M, Batko K, Śmiglewska A, Brzosko M, Stajszczyk M, Kwiatkowska B

doi: 10.1093/rheumatology/keae670

Related content

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: A nationwide cross-sectional study among > 12,000 patients

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Comorbidity in incident rheumatoid arthritis-a nationwide case-control study with bidirectional follow-up